Congressional Proposal Would Expand Generic Drug Manufacturers’ Duty to Warn

Today, the Senate and the U.S. House of Representatives introduced legislation that would fix the current discrepancy between holding generic and brand name manufacturers accountable for the safety of their drugs.

This legislation would allow generic manufacturers to initiate changes to their labels to reflect current health and safety information under the same circumstances that apply to manufacturers of branded drugs; ensuring brand and generic manufacturers have the same responsibility to adequately warn the public of their drugs’ risks.

The American Association for Justice (AAJ) has called for expanding generic drug manufacturers’ responsibility to warn since last June’s U.S. Supreme Court decision in Pliva v. Mensing and submitted comments supporting Public Citizen’s petition calling for a regulation change that would force generic manufacturers to update their labels.

To learn more, read AAJ’s full release on the introduction of the “Patient Safety and Generic Labeling Act.”